DoseRoutine

BPC-157 vs TB-500

Q: What's the main difference between BPC-157 and TB-500?

BPC-157 promotes healing largely by upregulating growth factors and angiogenesis (new blood vessel formation) at the site of injury. TB-500 (a synthetic fragment of Thymosin Beta-4) works systemically by sequestering G-actin, which drives cell migration, tissue remodeling and reduced inflammation.

Q: Can you stack BPC-157 and TB-500 together?

In performance and recovery communities the two are commonly stacked because their mechanisms are complementary (localized angiogenesis + systemic cell migration). Neither is FDA-approved and no controlled human trials evaluate the combination — talk to a qualified clinician before combining research peptides.

Q: Which one works faster?

BPC-157 has a short half-life (hours) and is typically dosed daily; anecdotal reports describe earlier localized improvement. TB-500 has a much longer half-life (days) and is commonly dosed 1–2× weekly, with more gradual systemic effects.

Q: Are BPC-157 and TB-500 legal?

Both are unapproved by the FDA for human use and are banned by WADA for competitive athletes. Legal status varies by jurisdiction — they are typically sold as research chemicals, not medicines.

The two most-searched healing peptides in the performance and longevity space. They're often lumped together, but the mechanisms are meaningfully different — and that difference matters when you're choosing one, dosing it, or stacking them for an injury protocol.

Read the full compound profiles

This page compares the two peptides. For complete dosing, research, and safety details, see the individual library entries.

BPC-157 library page TB-500 library page

Educational only

Neither BPC-157 nor TB-500 is FDA-approved for human use. Both are WADA-banned for competitive athletes. This page is a research summary, not a prescription. Talk to a licensed clinician before using either compound.

Mechanism: angiogenesis vs actin sequestering

BPC-157

Derived from a protective sequence found in human gastric juice. In animal models it upregulates VEGF, boosts angiogenesis (new blood vessel formation) and accelerates collagen synthesis at the site of injection. Effects tend to be local: tendons, ligaments, gut lining, joints near the injection site.

TB-500

A synthetic fragment of Thymosin Beta-4. Its headline mechanism is actin sequestering — binding G-actin so cells can migrate, differentiate and rebuild damaged tissue. Effects are systemic: it circulates and acts wherever cells need to move, which is why it's usually described as a whole-body recovery agent.

Side-by-side comparison

Attribute	BPC-157	TB-500
Class	Synthetic 15-amino-acid pentadecapeptide from gastric juice protein BPC	Synthetic 17-amino-acid fragment of Thymosin Beta-4 (Tβ4)
Primary mechanism	Upregulates VEGF and growth factors → angiogenesis + collagen synthesis at the injury site	Binds G-actin → drives cell migration, differentiation and tissue remodeling; anti-inflammatory
Best-studied use cases	Tendon, ligament and gut/GI healing; localized musculoskeletal recovery	Systemic soft-tissue recovery, muscle injury, cardiac tissue models
Typical research dose	200–500 mcg/day (SC or IM near site)	2–5 mg per injection, 1–2× per week
Half-life	Short (hours) — usually daily dosing	Long (days) — weekly dosing typical
Onset	Anecdotally faster for local injuries	Gradual, systemic
Route	Subcutaneous, intramuscular; oral forms exist but bioavailability is debated	Subcutaneous or intramuscular
Common side effects	Injection-site reaction; rare GI upset, dizziness, fatigue	Injection-site reaction; lethargy, transient head/muscle pain
Regulatory status	Not FDA-approved; WADA-prohibited	Not FDA-approved; WADA-prohibited
Stacks well with	TB-500, collagen peptides, GHK-Cu (skin/connective tissue)	BPC-157, IGF-1 LR3 (research contexts)

Which one fits your goal?

Choose BPC-157 if you're targeting a specific local injury (tendon, ligament, joint capsule, gut) and want daily, site-directed dosing.

Choose TB-500 if the injury is diffuse, multi-region, or you're recovering from a heavy training block and want a systemic agent with once-a-week dosing.

Stack them if you want complementary mechanisms — localized angiogenesis + systemic cell migration — for a bigger soft-tissue insult (post-surgery, chronic tendinopathy). This is common in the performance community but is not backed by controlled human trials.

A common stacking protocol

BPC-157: 250–500 mcg subcutaneous, once daily, 4–6 weeks near the injury site.
TB-500: 2–5 mg subcutaneous, twice weekly (loading phase 4 weeks) → 2 mg weekly maintenance.
Track pain, range-of-motion and function in DoseRoutine's check-in log to see whether the stack is actually moving the needle.

Educational only — not medical advice. See our medical disclaimer.

Frequently asked

What's the main difference between BPC-157 and TB-500?: BPC-157 acts locally by promoting angiogenesis and collagen synthesis at the injection site. TB-500 acts systemically by sequestering G-actin, driving cell migration and tissue remodeling throughout the body.
Can you stack them together?: Their mechanisms are complementary, which is why the stack is popular in recovery communities. There are no controlled human trials evaluating the combination — talk to a qualified clinician first.
Which one works faster?: BPC-157 has a short half-life and is dosed daily; anecdotal effects appear earlier for local injuries. TB-500 has a longer half-life (days) with more gradual systemic effects.
Are BPC-157 and TB-500 legal?: Neither is FDA-approved for human use, and both are WADA-prohibited for competitive athletes. Sold as research chemicals in most jurisdictions.

Jump back to the full compound guides or use DoseRoutine's peptide tools.

Full BPC-157 profile Full TB-500 profile Check interactions Reconstitution calculator